Recent evidence suggests that treatment with certain antihypertensive drugs may decrease the incidence of Alzheimer's disease (AD), while other work has failed to support this finding. We hypothesized that the apparent inconsistency could be due, in part, to unknown pharmacological features exerted by subsets of antihypertensive drugs. Based on this consideration, we initiated a high throughput screening of 55 antihypertensive drugs, which encompass almost all of the prescribed antihypertensive drugs representing all the clinically relevant antihypertensive pharmacological classes available. Excitingly, we identified 7 clinically prescribed antihypertensive drugs that significantly reduce the accumulation of total AD-type ?-amyloid (A?) in vitro and, as recently found, also in vivo in response to treatment with propranolol-HCI, nicardipine-HCI, losartan in Tg2576 mice, even when these drugs were delivered in a short term dosing regimen at concentrations ~2-3 folds lower than the recommended dose for hypertension in the absence of hypotensive side effects. Moreover, consistent, in part with a central role of high-molecular-weight (HMW)- soluble oligomeric A? species in the development of AD-type cognitive impairment, we found that coincidental with attenuation of memory deterioration, long-term valsartan, another antihypertensive drug with A? lowering properties identified in our high-throughput drug screening, significantly reduces ApMo/Api-42 and HMW soluble A? oligomeric content in the brain and plasma when delivered at subclinical doses. Finally, in molecular topological studies assessing the structural basis of Ap-lowering activity amongst the originally 55 antihypertensive-A? lowering agents screened, allowed us to identify 32 novel molecules that we plan to further characterize as novel Ap-lowering lead compounds. Collectively, the proposed studies in this revised U01 application will allow to continue the preclinical characterization of a select group of seven antihypertensive-A? lowering drugs in vivo for the treatment of AD (Aims 1-2) while in molecular topological studies we will continue the refinement of 32 refined A? lowering lead compounds as novel AP lowering agents for the treatment of AD.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01AG029310-03
Application #
7643129
Study Section
Special Emphasis Panel (ZAG1-ZIJ-3 (M1))
Program Officer
Buckholtz, Neil
Project Start
2007-09-15
Project End
2011-06-30
Budget Start
2009-07-01
Budget End
2010-06-30
Support Year
3
Fiscal Year
2009
Total Cost
$226,776
Indirect Cost
Name
Icahn School of Medicine at Mount Sinai
Department
Psychiatry
Type
Schools of Medicine
DUNS #
078861598
City
New York
State
NY
Country
United States
Zip Code
10029
Ho, Lap; Lange, Gudrun; Zhao, Wei et al. (2014) Select small nucleolar RNAs in blood components as novel biomarkers for improved identification of comorbid traumatic brain injury and post-traumatic stress disorder in veterans of the conflicts in Afghanistan and Iraq. Am J Neurodegener Dis 3:170-81
Gong, Bing; Pan, Yong; Vempati, Prashant et al. (2013) Nicotinamide riboside restores cognition through an upregulation of proliferator-activated receptor-? coactivator 1? regulated ?-secretase 1 degradation and mitochondrial gene expression in Alzheimer's mouse models. Neurobiol Aging 34:1581-8
Wang, Jun; Zhao, Zhong; Lin, Emi et al. (2013) Unintended effects of cardiovascular drugs on the pathogenesis of Alzheimer's disease. PLoS One 8:e65232
Pasinetti, Giulio M; Ho, Lap; Dooley, Christopher et al. (2012) Select non-coding RNA in blood components provide novel clinically accessible biological surrogates for improved identification of traumatic brain injury in OEF/OIF Veterans. Am J Neurodegener Dis 1:88-98
Tang, Cheuk Ying; Eaves, Emily; Dams-O'Connor, Kristen et al. (2012) Diffuse Disconnectivity in tBi: a resting state fMri anD Dti stuDy. Transl Neurosci 3:9-14
Wang, Jun; Ono, Kenjiro; Dickstein, Dara L et al. (2011) Carvedilol as a potential novel agent for the treatment of Alzheimer's disease. Neurobiol Aging 32:2321.e1-12
Varghese, Merina; Zhao, Wei; Wang, Jun et al. (2011) Mitochondrial bioenergetics is defective in presymptomatic Tg2576 AD mice. Transl Neurosci 2:
Ho, Lap; Fivecoat, Hayley; Wang, Jun et al. (2010) Alzheimer's disease biomarker discovery in symptomatic and asymptomatic patients: experimental approaches and future clinical applications. Exp Gerontol 45:15-22
Arrieta-Cruz, Isabel; Pavlides, Constantine; Pasinetti, Giulio Maria (2010) DEEP BRAIN STIMULATION IN MIDLINE THALAMIC REGION FACILITATES SYNAPTIC TRANSMISSION AND SHORTTERM MEMORY IN A MOUSE MODEL OF ALZHEIMER'S DISEASE. Transl Neurosci 1:188-194